Estimating costs of care for meningitis infections in low- and middle-income countries

Allison Portnoy, Mark Jit, Jeremy Lauer, Adriaan Blommaert, Sachiko Ozawa, Meghan Stack, Jillian Murray, Raymond Hutubessy

Research output: Contribution to journalArticle

Abstract

Meningitis infections are often associated with high mortality and risk of sequelae. The costs of treatment and care for meningitis are a great burden on health care systems, particularly in resource-limited settings. The objective of this study is to review data on the costs of care for meningitis in low- and middle-income countries, as well as to show how results could be extrapolated to countries without sound data.We conducted a systematic review of the literature from six databases to identify studies examining the cost of care in low- and middle-income countries for all age groups with suspected, probable, or confirmed meningitis. We extracted data on treatment costs and sequelae by infectious agent and/or pathogen, where possible. Using multiple regression analysis, a relationship between hospital costs and associated determinants was investigated in order to predict costs in countries with missing data. This relationship was used to predict treatment costs for all 144 low- and middle-income countries.The methodology of conducting a systematic review, extrapolating, and setting up a standard database can be used as a tool to inform cost-effectiveness analyses in situations where cost of care data are poor. Both acute and long-term costs of meningitis could be extrapolated to countries without reliable data. Although only bacterial causes of meningitis can be vaccine-preventable, a better understanding of the treatment costs for meningitis is crucial for low- and middle-income countries to assess the cost-effectiveness of proposed interventions in their country. This cost information will be important as inputs in future cost-effectiveness studies, particularly for vaccines.

Original languageEnglish (US)
Pages (from-to)A240-A247
JournalVaccine
Volume33
Issue numberS1
DOIs
StatePublished - May 7 2015

Fingerprint

meningitis
Meningitis
income
Costs and Cost Analysis
Health Care Costs
Infection
infection
cost effectiveness
Cost-Benefit Analysis
complications (disease)
systematic review
Vaccines
Databases
Bacterial Meningitides
vaccines
Hospital Costs
pathogens
health services
Age Groups
Regression Analysis

Keywords

  • Costs
  • Hospital
  • Meningitis
  • Resource-limited settings

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine
  • Medicine(all)

Cite this

Portnoy, A., Jit, M., Lauer, J., Blommaert, A., Ozawa, S., Stack, M., ... Hutubessy, R. (2015). Estimating costs of care for meningitis infections in low- and middle-income countries. Vaccine, 33(S1), A240-A247. https://doi.org/10.1016/j.vaccine.2014.11.061

Estimating costs of care for meningitis infections in low- and middle-income countries. / Portnoy, Allison; Jit, Mark; Lauer, Jeremy; Blommaert, Adriaan; Ozawa, Sachiko; Stack, Meghan; Murray, Jillian; Hutubessy, Raymond.

In: Vaccine, Vol. 33, No. S1, 07.05.2015, p. A240-A247.

Research output: Contribution to journalArticle

Portnoy, A, Jit, M, Lauer, J, Blommaert, A, Ozawa, S, Stack, M, Murray, J & Hutubessy, R 2015, 'Estimating costs of care for meningitis infections in low- and middle-income countries', Vaccine, vol. 33, no. S1, pp. A240-A247. https://doi.org/10.1016/j.vaccine.2014.11.061
Portnoy A, Jit M, Lauer J, Blommaert A, Ozawa S, Stack M et al. Estimating costs of care for meningitis infections in low- and middle-income countries. Vaccine. 2015 May 7;33(S1):A240-A247. https://doi.org/10.1016/j.vaccine.2014.11.061
Portnoy, Allison ; Jit, Mark ; Lauer, Jeremy ; Blommaert, Adriaan ; Ozawa, Sachiko ; Stack, Meghan ; Murray, Jillian ; Hutubessy, Raymond. / Estimating costs of care for meningitis infections in low- and middle-income countries. In: Vaccine. 2015 ; Vol. 33, No. S1. pp. A240-A247.
@article{95f43c66442f4476ba9bb6a1278d9907,
title = "Estimating costs of care for meningitis infections in low- and middle-income countries",
abstract = "Meningitis infections are often associated with high mortality and risk of sequelae. The costs of treatment and care for meningitis are a great burden on health care systems, particularly in resource-limited settings. The objective of this study is to review data on the costs of care for meningitis in low- and middle-income countries, as well as to show how results could be extrapolated to countries without sound data.We conducted a systematic review of the literature from six databases to identify studies examining the cost of care in low- and middle-income countries for all age groups with suspected, probable, or confirmed meningitis. We extracted data on treatment costs and sequelae by infectious agent and/or pathogen, where possible. Using multiple regression analysis, a relationship between hospital costs and associated determinants was investigated in order to predict costs in countries with missing data. This relationship was used to predict treatment costs for all 144 low- and middle-income countries.The methodology of conducting a systematic review, extrapolating, and setting up a standard database can be used as a tool to inform cost-effectiveness analyses in situations where cost of care data are poor. Both acute and long-term costs of meningitis could be extrapolated to countries without reliable data. Although only bacterial causes of meningitis can be vaccine-preventable, a better understanding of the treatment costs for meningitis is crucial for low- and middle-income countries to assess the cost-effectiveness of proposed interventions in their country. This cost information will be important as inputs in future cost-effectiveness studies, particularly for vaccines.",
keywords = "Costs, Hospital, Meningitis, Resource-limited settings",
author = "Allison Portnoy and Mark Jit and Jeremy Lauer and Adriaan Blommaert and Sachiko Ozawa and Meghan Stack and Jillian Murray and Raymond Hutubessy",
year = "2015",
month = "5",
day = "7",
doi = "10.1016/j.vaccine.2014.11.061",
language = "English (US)",
volume = "33",
pages = "A240--A247",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "S1",

}

TY - JOUR

T1 - Estimating costs of care for meningitis infections in low- and middle-income countries

AU - Portnoy, Allison

AU - Jit, Mark

AU - Lauer, Jeremy

AU - Blommaert, Adriaan

AU - Ozawa, Sachiko

AU - Stack, Meghan

AU - Murray, Jillian

AU - Hutubessy, Raymond

PY - 2015/5/7

Y1 - 2015/5/7

N2 - Meningitis infections are often associated with high mortality and risk of sequelae. The costs of treatment and care for meningitis are a great burden on health care systems, particularly in resource-limited settings. The objective of this study is to review data on the costs of care for meningitis in low- and middle-income countries, as well as to show how results could be extrapolated to countries without sound data.We conducted a systematic review of the literature from six databases to identify studies examining the cost of care in low- and middle-income countries for all age groups with suspected, probable, or confirmed meningitis. We extracted data on treatment costs and sequelae by infectious agent and/or pathogen, where possible. Using multiple regression analysis, a relationship between hospital costs and associated determinants was investigated in order to predict costs in countries with missing data. This relationship was used to predict treatment costs for all 144 low- and middle-income countries.The methodology of conducting a systematic review, extrapolating, and setting up a standard database can be used as a tool to inform cost-effectiveness analyses in situations where cost of care data are poor. Both acute and long-term costs of meningitis could be extrapolated to countries without reliable data. Although only bacterial causes of meningitis can be vaccine-preventable, a better understanding of the treatment costs for meningitis is crucial for low- and middle-income countries to assess the cost-effectiveness of proposed interventions in their country. This cost information will be important as inputs in future cost-effectiveness studies, particularly for vaccines.

AB - Meningitis infections are often associated with high mortality and risk of sequelae. The costs of treatment and care for meningitis are a great burden on health care systems, particularly in resource-limited settings. The objective of this study is to review data on the costs of care for meningitis in low- and middle-income countries, as well as to show how results could be extrapolated to countries without sound data.We conducted a systematic review of the literature from six databases to identify studies examining the cost of care in low- and middle-income countries for all age groups with suspected, probable, or confirmed meningitis. We extracted data on treatment costs and sequelae by infectious agent and/or pathogen, where possible. Using multiple regression analysis, a relationship between hospital costs and associated determinants was investigated in order to predict costs in countries with missing data. This relationship was used to predict treatment costs for all 144 low- and middle-income countries.The methodology of conducting a systematic review, extrapolating, and setting up a standard database can be used as a tool to inform cost-effectiveness analyses in situations where cost of care data are poor. Both acute and long-term costs of meningitis could be extrapolated to countries without reliable data. Although only bacterial causes of meningitis can be vaccine-preventable, a better understanding of the treatment costs for meningitis is crucial for low- and middle-income countries to assess the cost-effectiveness of proposed interventions in their country. This cost information will be important as inputs in future cost-effectiveness studies, particularly for vaccines.

KW - Costs

KW - Hospital

KW - Meningitis

KW - Resource-limited settings

UR - http://www.scopus.com/inward/record.url?scp=84928640464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928640464&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2014.11.061

DO - 10.1016/j.vaccine.2014.11.061

M3 - Article

C2 - 25919168

AN - SCOPUS:84928640464

VL - 33

SP - A240-A247

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - S1

ER -